Trials / Completed
CompletedNCT05895994
Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematological Malignancies
A Study on the Efficacy, Safety and Cellular Pharmacokinetics of RD13-02 Cell Injection in Patients With Relapsed or Refractory CD7-positive Hematological Malignancies
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- MEI HENG · Academic / Other
- Sex
- All
- Age
- 3 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 Chimeric Antigen Receptor-T(CAR-T) therapy for patients with CD7-positive relapsed or refractory T-Acute Lymphoblastic Leukemia(ALL)/Lymphoblastic Lymphoma(LBL)/Acute Myelogenous Leukemia(AML), and to evaluate the pharmacokinetics of CD7 CAR-T in patients。
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RD13-02 cell infusion | CAR-T cells |
Timeline
- Start date
- 2023-03-10
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
- First posted
- 2023-06-09
- Last updated
- 2026-02-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05895994. Inclusion in this directory is not an endorsement.